Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
NYSE MKT:LCTX
Holding LCTX?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.03Last Year’s EPS
-$0.03Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -36.95%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call was generally positive with significant achievements such as extending the cash runway, progress with the FDA, increased revenue, and reduced net loss. However, there were some challenges, particularly regarding delays in the OPC1 study and manufacturing hurdles.Company Guidance
During the third-quarter 2024 earnings call for Lineage Cell Therapeutics, the company provided updated guidance, highlighting an extended cash runway expected to support operations into the first quarter of 2026, driven by fiscal discipline and interactions with the FDA related to the OPC1 program. The company's financials revealed cash, cash equivalents, and marketable securities totaling $32.7 million as of September 30, 2024, with total revenues increasing to $3.8 million, primarily due to collaboration revenue from Roche. Operating expenses decreased slightly to $7.6 million, with a net loss reduced to $3 million or $0.02 per share, compared to $7.1 million or $0.04 per share in the same period of 2023. The company remains optimistic about the progress of its OpRegen program, noting Roche's continued investment and actions, and is poised to advance its OPC1 program with anticipated FDA review completion and study enrollment in early 2025.Extended Cash Runway
Lineage Cell Therapeutics has updated its cash runway guidance, now expected to support planned operations into Q1 of 2026, extended from previous guidance due to fiscal discipline and interactions with the FDA.
FDA Progress on OPC1 DOSED Study
A meeting with FDA reviewers provided a clear path to commencing enrollment in the DOSED study for OPC1, with FDA indicating no further information requests are expected.
OpRegen Program Advancements
Roche and Genentech have shown increased investment in the OpRegen program, with positive indicators such as RMAT designation and ongoing patient follow-up for an additional 5 years.
Revenue Increase
Total revenues for the quarter were $3.8 million, a net increase of $2.5 million compared to the same period in 2023, driven by more collaboration revenue recognized under the agreement with Roche.
Reduced Net Loss
The net loss for the quarter was $3 million or $0.02 per share, compared to a net loss of $7.1 million or $0.04 per share for the same period in 2023.
---
LCTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LCTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.88 | $0.86 | -2.27% |
| Aug 08, 2024 | $0.88 | $0.90 | +2.27% |
| May 09, 2024 | $1.18 | $1.17 | -0.85% |
| Mar 07, 2024 | $1.13 | $1.30 | +15.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?
Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?
Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LCTX EPS forecast?
LCTX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.03.
---